Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement

22 Jul 2020

• By Sten Stovall

Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.

Foot_Ulcer — Reapplix’s 3CPatch System repairs hard-to-heal diabetic foot ulcers. • Source: Shutterstock

Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement

More from Diabetic Care

More from Device Area